Vaxart (NASDAQ:VXRT) released its earnings results on Sunday. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04), Briefing.com reports. The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.62 million. Vaxart had a negative return on equity of 84.90% and a negative net margin of 281.50%. The company’s revenue for the quarter was down 82.8% compared to the same quarter last year.
VXRT stock traded up $0.51 during mid-day trading on Tuesday, hitting $8.53. The stock had a trading volume of 1,016,340 shares, compared to its average volume of 18,688,678. Vaxart has a 1-year low of $2.23 and a 1-year high of $24.90. The company has a fifty day moving average of $6.40 and a 200 day moving average of $6.87. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of -15.93 and a beta of -0.11.
VXRT has been the subject of several research reports. Zacks Investment Research downgraded Vaxart from a “hold” rating to a “sell” rating in a research note on Tuesday, March 9th. B. Riley reissued a “buy” rating and set a $13.00 price target (down from $16.00) on shares of Vaxart in a research report on Thursday, March 4th.
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection.
Featured Story: Street Name
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.